IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma

Journal of Viral Hepatitis

Volumn 18, Issue 10, 2011, Pages

  Kawaoka, T ^a,b   Aikata, H ^a   Takaki, S ^a   Hiramatsu, A ^a   Waki, K ^a   Hiraga, N ^a   Miki, D ^a,b   Tsuge, M ^a   Imamura, M ^a   Kawakami, Y ^a   Takahashi, S ^a   Ochi, H ^a,b   Tashiro, H ^c   Ohdan, H ^c   Chayama, K ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

curative treatment; hepatitis C virus; hepatocellular carcinoma; interleukin 28B; pegylated interferon alpha plus ribavirin combination therapy

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; INTERLEUKIN 28B; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HEPATITIS C VIRUS; HUMAN; INDEPENDENT VARIABLE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; SURVIVAL RATE; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECURRENCE; RIBAVIRIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 80052865178     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01468.x     Document Type: Article

References (43)

1. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M,. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995; 21: 650-655.
2. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-1801. (Pubitemid 23174709)
3. Shiratori Y, Shiina S, Imamura M, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology 1995; 22: 1027-1033.
4. Ikeda K, Saitoh S, Tsubota A, et al. Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer 1993; 71: 19-25. (Pubitemid 23019276)
5. Kubo S, Nishiguchi S, Shuto T, et al. Effects of continuous hepatitis with persistent hepatitis C viremia on outcome after resection of hepatocellular carcinoma. Jpn J Cancer Res 1999; 90: 162-170. (Pubitemid 29112316)
6. Kumada T, Nakano S, Takeda I, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997; 25: 87-92. (Pubitemid 27014990)
7. Nagasue N, Uchida M, Makino Y, et al. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology 1993; 105: 488-494. (Pubitemid 23213535)
8. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321: 1501-1506. (Pubitemid 20015540)
9. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-1510.
10. Jeong S, Aikata H, Katamura Y, et al. Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. World J Gastroenterol 2007; 13: 5188-5195. (Pubitemid 47527735)
11. Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44: 1543-1554. (Pubitemid 44970357)
12. Sakaguchi Y, Kudo M, Fukunaga T, Minami Y, Chung H, Kawasaki T,. Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005; 48: 64-70. (Pubitemid 40529213)
13. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H,. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002; 89: 418-422. (Pubitemid 34595504)
14. Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000; 32: 228-232. (Pubitemid 30614654)
15. Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001; 134: 963-967. (Pubitemid 32466235)
16. Nishiguchi S, Tamori A, Kubo S,. Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005; 48: 71-75. (Pubitemid 40529214)
17. Suou T, Mitsuda A, Koda M, et al. Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study. Hepatol Res 2001; 20: 301-311. (Pubitemid 32573892)
18. Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003; 138: 299-306. (Pubitemid 36205926)
19. Lin SM, Lin CJ, Hsu CW, et al. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004; 100: 376-382.
20. Hung CH, Lee CM, Wang JH, Tung HD, Chen CH, Lu SN,. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol 2005; 20: 1553-1559.
21. Jeong SC, Aikata H, Katamura Y, et al. Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J Gastroenterol 2007; 13: 5343-5350. (Pubitemid 47559465)
22. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965. (Pubitemid 32913521)
23. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
24. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
25. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
26. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
27. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
28. Kawaoka T, Hayes CN, Ohishi W, et al. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J Hepatol 2011; 54: 408-414.
29. Mangia A, Thompson AJ, Santoro R, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-827.
30. Huang JF, Yu ML, Huang CF, et al. The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies-a multicenter prospective trial. J Hepatol 2011; 54: 219-226.
31. Hagihara H, Nouso K, Kobayashi Y, et al. Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int J Clin Oncol 2010; doi:.
32. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. Jpn J Surg 1989; 19: 98-129.
33. Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y,. A high-throughput SNP typing system for genome-wide association studies. J Hum Genet 2001; 46: 471-477. (Pubitemid 32744120)
34. Suzuki A, Yamada R, Chang X, et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003; 34: 395-402. (Pubitemid 36935332)
35. Kitamura S, Tsuge M, Hatakeyama T, et al. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy. Antivir Ther 2010; 15: 1087-1097.
36. Mori N, Imamura M, Kawakami Y, et al. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy. J Med Virol 2009; 81: 640-649.
37. Kawaoka T, Hiraga N, Takahashi S, et al. Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus. Scand J Gastroenterol 2010; 45: 1488-1496.
38. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ,. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-1520. (Pubitemid 24166476)
39. Tomimaru Y, Nagano H, Eguchi H, et al. Effects of preceding interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma. J Surg Oncol 2010; 102: 308-314.
40. Elefsiniotis IS, Vezali E, Mihas C, Saroglou G,. Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin. Intervirology 2009; 52: 247-251.
41. Lagging M, Wejstal R, Uhnoo I, et al. Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations. Scand J Infect Dis 2009; 41: 389-402.
42. Reau N, Satoskar R, Te H, et al. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Am J Gastroenterol 2011; 106: 452-458.
43. Pearlman BL, Ehleben C, Saifee S,. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007; 46: 1688-1694.